

## **References – Dr. Alan List's Presentation, "Myelodysplastic Syndromes"**

1. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. *Blood* 2008 July 1, 112(1):45-52. Epub 2008 Apr 28. PMID: 18443215.
2. Giulio Genovese, Ph.D., Anna K. Kähler, Ph.D., Robert E. Handsaker, B.S., Johan Lindberg, Ph.D., Samuel A. Rose, B.S., Samuel F. Bakhom, M.D., Ph.D., Kimberly Chambert, M.S., Eran Mick, B.S., Benjamin M. Neale, Ph.D., Menachem Fromer, Ph.D., Shaun M. Purcell, Ph.D., Oscar Svantesson, M.S., Mikael Landén, Ph.D., Martin Höglund, M.D., Ph.D., Sören Lehmann, M.D., Ph.D., Stacey B. Gabriel, Ph.D., Jennifer L. Moran, Ph.D., Eric S. Lander, Ph.D., Patrick F. Sullivan, M.D., Pamela Sklar, M.D., Ph.D., Henrik Grönberg, M.D., Ph.D., Christina M. Hultman, Ph.D., and Steven A. McCarroll, Ph.D. Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. *N Engl J Med* 2014; 371:2477-2487
3. J. M. Bennett, D. Catovsky, M. T. Daniel, G. Flandrin, D. A. G. Galton, H. R. Gralnick and C. Sultan. Proposals for the classification of the myelodysplastic syndromes. *BJH*, vol.51, issue 2, p. 189-199, June 1982.
4. Nancy Lee Harris, Elaine S. Jaffe, Jacques Diebold, Georges Flandrin, H. Konrad Muller-Hermelink, James Vardiman, T. Andrew Lister, and Clara D. Bloomfield. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997, *JCO* Dec 1, 1999:3835-3849.
5. Ulrich Germing, Norbert Gattermann, Corinna Strupp, Manuel Aivado, Carlo Aul. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. *Leukemia Research*. Volume 24, Issue 12, Pages 983-1066 (December 2000).
6. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood* 2009;114(5):937-951
7. Herman Van Den Berghe, Jean-Jacques Cassiman, Guido David, Jean-Pierre Fryns, Jean-Louis Michaux & Gerard Sokal. Distinct haematological disorder with deletion of long arm of No. 5 chromosome 437. *Nature*, 251. P 437-438, October 1974.
8. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood* 1997;89(6):2079-2088
9. Benjamin L. Ebert, Jennifer Pretz, Jocelyn Bosco, Cindy Y. Chang, Pablo Tamayo, Naomi Galili, Azra Raza, David E. Root, Eyal Attar, Steven R. Ellis & Todd R. Golub. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. *Nature*, p335, Jan 2008.
10. Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati, Sudhir Tauro, Gunes Gundem, Peter Van Loo, Chris J. Yoon, Peter Ellis, David C. Wedge, Andrea Pellagatti, Adam Shlien, Michael John Groves, Simon A. Forbes, Keiran Raine, Jon Hinton, Laura J.

Mudie, Stuart McLaren, Claire Hardy, Calli Latimer, Matteo G. Della Porta, Sarah O'Meara, Iliaria Ambaglio, Anna Galli, Adam P. Butler, Gunilla Walldin, Jon W. Teague, Lynn Quek, Alex Sternberg, Carlo Gambacorti-Passerini, Nicholas C. P. Cross, Anthony R. Green, Jacqueline Boultonwood, Paresh Vyas, Eva Hellstrom-Lindberg, David Bowen, Mario Cazzola, Michael R. Stratton, and Peter J. Campbell. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood* 2013 122(22). 3616-27.

11. Rafael Bejar and Omar Abdel-Wahab. The importance of subclonal genetic events in MDS. *Blood* 2013 122(22) 3550-1.
12. T Haferlach, Y Nagata, V Grossmann, Y Okuno, U Bacher, G Nagae, S Schnittger, M Sanada, A Kon, T Alpermann, K Yoshida, A Roller, N Nadarajah, Y Shiraishi, Y Shiozawa, K Chiba, H Tanaka, H P Koeffler, H-U Klein, M Dugas, H Aburatani, A Kohlmann, S Miyano, C Haferlach, W Kern and S Ogawa. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia*. Vol. 28, p. 241-247. 2014.
13. Austin G. Kulasekararaj, Alexander E. Smith, Syed A. Mian, Azim M. Mohamedali, Pramila Krishnamurthy, Nicholas C. Lea, Joop Gäken, Coralie Pennaneach, Robin Ireland, Barbara Czepulkowski, Sabine Pomplun, Judith C. Marsh and Ghulam J. Mufti. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. *BJH*, vol. 160, issue 5, p. 660-672. Mar 2013.
14. Eva Hellström-Lindberg, Robert Negrin, Richard Stein, Sanford Krantz, Greger Lindberg, James Vardiman, Åke Öst and Peter Greenberg. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. *BJH*, vol 97, issue 2, p 344-351, Nov 1997.
15. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. *N Engl J Med*. 2006 October 355(14):1456-65.
16. Mar Mallo, Mónica del Rey, Mariam Ibáñez, M<sup>a</sup> José Calasanz, Leonor Arenillas, M<sup>a</sup> José Larráyo, Carmen Pedro, Andrés Jerez, Jaroslaw Maciejewski, Dolors Costa, Meritxell Nomdedeu, María Díez-Campelo, Eva Lumbreras, Teresa González-Martínez, Isabel Marugán, Esperanza Such, José Cervera, Juan C. Cigudosa, Sara Álvarez, Lourdes Florensa, Jesús M<sup>a</sup> Hernández and Francesc Solé. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. *BJH*, vol. 162, issue 1, p. 74–86. July 2013.
17. Rebekka K. Schneider, Vera Ademà, Dirk Heckl, Marcus Järås, Mar Mallo, Allegra M. Lord, Lisa P. Chu, Marie E. McConkey, Rafael Kramann, Ann Mullally, Rafael Bejar, Francesc Solé, Benjamin L. Ebert. Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS. *Cancer Cell*. P. 509-520, September 2014.
18. Benjamin L. Ebert, Jennifer Pretz, Jocelyn Bosco, Cindy Y. Chang, Pablo Tamayo, Naomi Galili, Azra Raza, David E. Root, Eyal Attar, Steven R. Ellis & Todd R. Golub.

Identification of RPS14 as a 5q<sup>-</sup> syndrome gene by RNA interference screen. *Nature*, vol. 451 (7176) p335-339, January 2008.

19. Jan Kronke, Emma C. Fink, Benjamin L. Ebert, Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS. *Nature*, 523, 183-188, July 2015.
20. Pierre **Fenaux**, Ghulam J Mufti, Eva Hellstrom-Lindberg, Valeria Santini, Carlo Finelli, Aristoteles Giagounidis, Robert Schoch, Norbert Gattermann, Guillermo Sanz, Alan List, Steven D Gore, John F Seymour, John M Bennett, John Byrd, Jay Backstrom, Linda Zimmerman, David McKenzie, CL Beach, Lewis R Silverman. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *The Lancet Oncology*, Volume 10, Issue 3, March 2009, Pages 223-232.
21. Matteo G. Della Porta, Emilio Paolo Alessandrino, Andrea Bacigalupo, Maria Teresa van Lint, Luca Malcovati, Cristiana Pascutto, Michele Falda, Massimo Bernardi, Francesco Onida, Stefano Guidi, Anna Paola Iori, Raffaella Cerretti, Paola Marengo, Pietro Pioltelli, Emanuele Angelucci, Rosi Oneto, Francesco Ripamonti, Paolo Bernasconi, Alberto Bosi, Mario Cazzola, Alessandro Rambaldi. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. *Blood* 2014 123:2333-2342;
22. M Robin, R Porcher, L Adès, E Raffoux, M Michallet, S François, J-Y Cahn, A Delmer, E Wattel, S Vigouroux, J-O Bay, J Cornillon, A Huynh, S Nguyen, M-T Rubio, L Vincent, N Maillard, A Charbonnier, R P de Latour, O Reman, H Dombret, P Fenaux and G Socié. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. *Leukemia*. 2015 Jul p. 1496-501.
23. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. *J Clin Oncol*. 2012 Mar 10;30(8):820-9. Epub 2012 Feb 13.
24. Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. *Am J Hematol*. 2013 Jul;88(7):566-70. Epub 2013 May 30.
25. R Bejar. Clinical and genetic predictors of prognosis in myelodysplastic syndromes *Haematologica*, 2014 Jun;99(6):956-64. PMID: 24881041.
26. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. *Haematologica*. 2006 Dec;91(12):1588-90. PMID: 17145593.

27. C. Bally, L. Ades, A. Renneville, C. Preudhomme, S. Raynaud, T. Cluzeau, V. Eclache, M. Hunault-Berger, and others. P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q. *Leukemia Research*, Vol. 37, S32–S33. Published in issue: May 2013.
28. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu J, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. A critical role for phosphatase haploinsufficiency in the selective suppression of deletion 5q MDS by lenalidomide. *PNAS*. Aug 4 2009, 106 (31):12974-12979; Epub May 18 2009. PMID: 19470455.
29. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL. J Clin Oncol. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. 2009 Apr 10;27(11):1850-6. Epub 2009 Mar 2.
30. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. *Ann Intern Med*. 2001 Apr 3;134(7):573-86.
31. Pr  bet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Ad  s L, Quesnel B, Beach CL, Fenaux P, Vey N. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. *J Clin Oncol*. 2011 Aug 20;29(24):3322-7. Epub 2011 Jul 25.
32. Karen Lin, Tea Reljic, Ambuj Kumar, Jeffrey E. Lancet, Alan F. List, and Rami S. Komrokji. Poor Outcome of Patients with Myelodysplastic Syndrome (MDS) After Azacitidine Treatment Failure. *Blood (ASH Annual Meeting Abstracts)*, Nov 2010; 116: 2913.
33. Hoffman R, Benz E, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P. *Hematology: Basic Principles and Practice*, 3e. Churchill Livingstone; 3 edition (September 2, 1999).
34. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. *Nature*. 1974 Oct 4;251(5474):437-8. PMID: 4421285
35. Lai F1, Godley LA, Joslin J, Fernald AA, Liu J, Espinosa R 3rd, Zhao N, Pamintuan L, Till BG, Larson RA, Qian Z, Le Beau MM. Genomics. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). 2001 Jan 15;71(2):235-45.
36. Jaju RJ<sup>1</sup>, Boulton J, Oliver FJ, Kostrzewa M, Fidler C, Parker N, McPherson JD, Morris SW, M  ller U, Wainscoat JS, Kearney L. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. *Genes Chromosomes Cancer*. 1998 Jul;22(3):251-6.